AbbVie Inc. (ABBV) Institutional Ownership & Insider Trading

4,199 institutions reported holding AbbVie Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 6 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ABBVAbbVie Inc.Follow ABBV — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 504.8B
P/E TTM: 80.7
Dividend yield: 2.4%
52-week: —
Next earnings: 30 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

4,199 institutions held 75.6% of the shares. Across filers that reported both quarters, shares held changed +1.1%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	4,199	1336	+1.1%	1445	203	1140	78
Mar 26	4,030	1295	-0.2%	1267	94	1261	134
Dec 25	4,019	1311	-3.2%	1133	92	1194	91
Sep 25	3,811	1323	+4.2%	1166	211	1051	68
Jun 25	3,685	1284	+0.2%	1247	96	1074	130
Mar 25	3,698	1255	+0.3%	1079	182	1242	81
Dec 24	3,582	1276	-3.4%	1083	79	1031	102
Sep 24	3,392	1243	-3.5%	976	156	1004	53

AbbVie Inc. — questions

Who owns AbbVie Inc. stock?: 4,199 institutions reported AbbVie Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (8.5%), VANGUARD CAPITAL MANAGEMENT LLC (6.5%), STATE STREET CORP (4.7%).
Are AbbVie Inc. insiders buying or selling?: 6 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from AbbVie Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.